Overcoming The Hurdles of Starting up a Biopharmaceutical Company

Every emerging biopharmaceutical company has an interesting story that describes how they overcame major startup challenges, including study design, funding, and drug targeting strategies. eXIthera is developing a small molecule, EP-7041, to control the blood-clotting pathway and enable healthy blood flow without the concerns of adverse clotting or major bleeding via selective inhibition of Factor XIa. In this interview, Moe Alsumidaie speaks with Neil Hayward, PhD, CEO of eXIthera, to advise on his experience overcoming the challenges of starting up an emerging biopharmaceutical company.

Read More